CA2522899A1 - Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) - Google Patents
Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) Download PDFInfo
- Publication number
- CA2522899A1 CA2522899A1 CA002522899A CA2522899A CA2522899A1 CA 2522899 A1 CA2522899 A1 CA 2522899A1 CA 002522899 A CA002522899 A CA 002522899A CA 2522899 A CA2522899 A CA 2522899A CA 2522899 A1 CA2522899 A1 CA 2522899A1
- Authority
- CA
- Canada
- Prior art keywords
- phenylamino
- methylethyl
- fluorophenyl
- pyrrole
- dihydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005370 atorvastatin Drugs 0.000 title abstract 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 238000001069 Raman spectroscopy Methods 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-(.beta., .DELTA.;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt atorvastatin designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30204901P | 2001-06-29 | 2001-06-29 | |
US60/302,049 | 2001-06-29 | ||
CA002450111A CA2450111C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002450111A Division CA2450111C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2522899A1 true CA2522899A1 (en) | 2003-01-16 |
CA2522899C CA2522899C (en) | 2006-04-25 |
Family
ID=35452260
Family Applications (14)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002521933A Expired - Fee Related CA2521933C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521792A Expired - Fee Related CA2521792C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521833A Expired - Fee Related CA2521833C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521956A Expired - Fee Related CA2521956C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521887A Expired - Fee Related CA2521887C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521980A Expired - Fee Related CA2521980C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521891A Expired - Fee Related CA2521891C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521953A Expired - Fee Related CA2521953C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521828A Expired - Fee Related CA2521828C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521958A Expired - Fee Related CA2521958C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-pheyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521908A Expired - Fee Related CA2521908C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002522899A Expired - Fee Related CA2522899C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521993A Abandoned CA2521993A1 (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of ¬r-(r*,r*)|-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-¬(phenylamino)carbonyl|-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521776A Expired - Fee Related CA2521776C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
Family Applications Before (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002521933A Expired - Fee Related CA2521933C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521792A Expired - Fee Related CA2521792C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521833A Expired - Fee Related CA2521833C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521956A Expired - Fee Related CA2521956C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521887A Expired - Fee Related CA2521887C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521980A Expired - Fee Related CA2521980C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521891A Expired - Fee Related CA2521891C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
CA002521953A Expired - Fee Related CA2521953C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521828A Expired - Fee Related CA2521828C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521958A Expired - Fee Related CA2521958C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-pheyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521908A Expired - Fee Related CA2521908C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002521993A Abandoned CA2521993A1 (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of ¬r-(r*,r*)|-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-¬(phenylamino)carbonyl|-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
CA002521776A Expired - Fee Related CA2521776C (en) | 2001-06-29 | 2002-05-21 | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
Country Status (1)
Country | Link |
---|---|
CA (14) | CA2521933C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8080672B2 (en) | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
-
2002
- 2002-05-21 CA CA002521933A patent/CA2521933C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521792A patent/CA2521792C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521833A patent/CA2521833C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521956A patent/CA2521956C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521887A patent/CA2521887C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521980A patent/CA2521980C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521891A patent/CA2521891C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521953A patent/CA2521953C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521828A patent/CA2521828C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521958A patent/CA2521958C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521908A patent/CA2521908C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002522899A patent/CA2522899C/en not_active Expired - Fee Related
- 2002-05-21 CA CA002521993A patent/CA2521993A1/en not_active Abandoned
- 2002-05-21 CA CA002521776A patent/CA2521776C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2521887A1 (en) | 2003-01-16 |
CA2521956A1 (en) | 2003-01-16 |
CA2521887C (en) | 2006-04-25 |
CA2521953C (en) | 2006-03-14 |
CA2521833C (en) | 2006-04-25 |
CA2521776C (en) | 2006-04-25 |
CA2521828A1 (en) | 2003-01-16 |
CA2521833A1 (en) | 2003-01-16 |
CA2521891C (en) | 2006-04-25 |
CA2521993A1 (en) | 2003-01-16 |
CA2521958A1 (en) | 2003-01-16 |
CA2521953A1 (en) | 2003-01-16 |
CA2521980C (en) | 2006-08-29 |
CA2521891A1 (en) | 2003-01-16 |
CA2521792C (en) | 2006-04-25 |
CA2521908A1 (en) | 2003-01-16 |
CA2521792A1 (en) | 2003-01-16 |
CA2521776A1 (en) | 2003-01-16 |
CA2521933C (en) | 2006-03-21 |
CA2521828C (en) | 2006-04-25 |
CA2521980A1 (en) | 2003-01-16 |
CA2521958C (en) | 2006-08-29 |
CA2521956C (en) | 2006-04-25 |
CA2521933A1 (en) | 2003-01-16 |
CA2521908C (en) | 2006-04-25 |
CA2522899C (en) | 2006-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2450111A1 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) | |
CA2220018A1 (en) | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) | |
IL122162A0 (en) | Crystalline form III atorvastatin and pharmceutical compositions containing it | |
EP2540704A3 (en) | Benethamine salt forms of atorvastatin | |
NZ533935A (en) | Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1) | |
CA2522899A1 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190521 |